Antimicrobial peptide coatings for hydroxyapatite:electrostatic and covalent attachment of antimicrobial peptides to surfaces by Townsend, Leigh et al.
 
 
Antimicrobial peptide coatings for hydroxyapatite
Townsend, Leigh ; Williams, Richard; Anuforom, Olachi; Berwick, Matthew; Halstead, Fenella;
Hughes, Erik; Stamboulis, Artemis; Oppenheim, Beryl; Gough, Julie E.; Grover, Liam; Scott,
Robert; Webber, Mark; Peacock, Anna; Belli, Antonio; Logan, Ann; De Cogan, Felicity
DOI:
10.1098/rsif.2016.0657
License:
None: All rights reserved
Document Version
Peer reviewed version
Citation for published version (Harvard):
Townsend, L, Williams, R, Anuforom, O, Berwick, M, Halstead, F, Hughes, E, Stamboulis, A, Oppenheim, B,
Gough, JE, Grover, L, Scott, R, Webber, M, Peacock, A, Belli, A, Logan, A & De Cogan, F 2017, 'Antimicrobial
peptide coatings for hydroxyapatite: electrostatic and covalent attachment of antimicrobial peptides to surfaces',
Journal of The Royal Society Interface, vol. 14, no. 126. https://doi.org/10.1098/rsif.2016.0657
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Published as: Townsend, Leigh, et al. "Antimicrobial peptide coatings for hydroxyapatite: electrostatic and covalent attachment of
antimicrobial peptides to surfaces." Journal of The Royal Society Interface (2017)
Checked 28/3/17
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
Antimicrobial	Peptide	Coatings	for	Hydroxyapatite:	Electrostatic	and	Covalent	attachment	of	
Antimicrobial	Peptides	to	Surfaces.	
Leigh	Townsend1,	Richard	Williams2,9,	Olachi	Anuforom1,	Matthew	R	Berwick3,	Fenella	
Halstead4,9,	E	Hughes2,	Artemis	Stamboulis5,	Beryl	Oppenheim4,9,	Julie	Gough8,	Liam	
Grover2,9,	Rob	Scott6,9,	Mark	Webber7,9,	Anna	FA	Peacock3,	Antonio	Belli1,9,	Ann	Logan1,9,	
Felicity	de	Cogan1,9	
	
1. Institute	of	Inflammation	and	Ageing,	University	of	Birmingham,	B15	2TT,	UK	
2. School	of	Chemical	Engineering,	University	of	Birmingham,	B15	2TT,	UK	
3. School	of	Chemistry,	University	of	Birmingham,	B15	2TT,	UK	
4. University	Hospitals	Birmingham	NHS	Foundation	Trust,	Birmingham,	B15	2TH,	UK		
5. School	of	Metallurgy	and	Materials,	University	of	Birmingham,	B15	2TT,	UK	
6. Royal	Centre	for	Defence	Medicine,	Birmingham,	B15	2TH,	UK	
7. Institute	of	Microbiology	and	Infection,	College	of	Medical	and	Dental	Sciences,	
University	of	Birmingham,	B15	2TT,	UK	
8. School	of	Materials,	University	of	Manchester,	Manchester,	M1	7HS,	UK	
9. NIHR	Surgical	Reconstruction	and	Microbiology	Research	Centre,	Queen	Elizabeth	
Hospital,	Birmingham,	B15	2TH,	UK	
	
*Corresponding	author:	
Institute	of	Inflammation	and	Ageing,		
University	of	Birmingham,	B15	2TT,	UK	
Email:	F.deCogan@bham.ac.uk	
Tel:	0121	414	8859	
Abstract	
The	interface	between	implanted	devices	and	their	host	tissue	is	complex	and	is	often	
optimised	for	maximal	integration	and	cell	adhesion.	However,	this	also	gives	a	surface	
suitable	for	bacterial	colonisation.	We	have	developed	a	novel	method	of	modifying	the	
surface	at	the	material-tissue	interface	with	an	antimicrobial	peptide	coating	to	allow	cell	
attachment	while	inhibiting	bacterial	colonisation.	The	technology	reported	here	is	a	dual	
antimicrobial	peptide	coating.	The	dual	coating	consists	of	antimicrobial	peptides	covalently	
bonded	to	the	hydroxyapatite	surface,	followed	by	deposition	of	electrostatically	bound	
antimicrobial	peptides.	The	dual	approach	gives	an	efficacious	coating	which	is	stable	for	
over	12	months	and	can	prevent	colonisation	of	the	surface	by	both	gram	positive	and	gram	
negative	bacteria.			
	
	
	
Background	
Infection	is	recognised	as	one	of	the	leading	complications	of	bone	replacement	implant	
operations	within	the	orthopaedics	fields,	with	2.8	%	of	operations	contracting	a	surgical	
site	infection1.	While	acute	infections	occur	immediately,	it	is	common	for	some	infections,	
particularly	prosthetic	joint	infections,	to	be	detected	over	1	year	following	the	implantation	
of	the	device.	These	infections	are	often	a	complex	and	challenging	complication	to	prevent	
or	treat2.		
The	bacteria	most	commonly	associated	with	infection	in	orthopaedic	implants	are	Gram	
positive	bacteria	-	coagulase-negative	Staphylococcus	epidermidis	(S.	epidermidis),	
Staphylococcus	aureus	(S.	aureus),	(both	methicillin-sensitive	and	resistant)	and	
Enterococcus	spp.,	which	are	responsible	for	75	%	of	all	implant	infections3	and	Gram	
negative	bacteria	-	Pseudomonas	aeruginosa	(P.	aeruginosa).	Current	clinical	practice	for	
treating	infection	around	an	implant	site	is	an	extended	course	of	antibiotics.	However,	
systemic	and	oral	administration	of	antibiotics	often	results	in	low	availability	at	the	site	of	
infection4	Bacteria	can	also	colonise	the	implant	forming	a	biofilm	on	the	surface	resulting	in	
infection5.	This	type	of	infection	is	difficult	to	treat	as	the	dense	extracellular	matrix	
associated	with	the	biofilm	acts	a	barrier	against	detergents	and	antibiotics,	with	further	
complications	presented	by	the	rise	of	multi-resistant	bacteria	such	as	methicillin-resistant	
S.	aureus	(MRSA)6.	Well	established	infection	around	the	implant	results	in	necrosis	of	the	
surrounding	tissue	often	requiring	surgical	debridement.	Extensive	tissue	necrosis	breaks	
down	the	bone-implant	interface,	causing	loosening	of	the	implant	and	loss	of	limb	function,	
which	then	requires	surgical	retrieval	and	replacement	of	the	implant7,8.	Implant	retrieval	
not	only	incurs	significant	financial	costs	and	patient	discomfort,	but	the	procedure	also	
results	in	further	bone	tissue	loss,	meaning	that	implant	replacement	can	only	be	performed	
a	limited	number	of	times	over	the	lifetime	of	the	patient.	
The	use	of	titanium	for	the	manufacture	of	bone	replacement	implants	is	well	established	as	
a	result	of	its	high	strength	and	stiffness	properties,	along	with	its	corrosion	resistance	and	
excellent	biocompatibility	in	bone	replacement	applications9.	Hydroxyapatite	(HA)	is	a	
mineral	with	similar	chemical	composition	to	the	mineral	fraction	of	human	bone	and	is	
used	as	a	coating	on	metal	implants	to	promote	osseointegration10,11.	Currently,	HA	coatings	
are	being	used	to	coat	cement-less	implants	and	to	promote	bone	ingrowth12.	Many	reports	
suggest	that	HA	coatings	on	metal	implants	precipitate	faster	than	bone	fixation,	resulting	in	
a	reduction	of	pain	and	recovery	time	for	implant	patients13,14.	Self-cleaning	surfaces	are	
well	established	in	the	natural	world	to	prevent	bacterial	adhesion15.		
There	are	an	array	of	technologies	which	can	be	used	to	deposit	coatings	on	surfaces.	These	
include	the	deposition	of	patterned	hydroxyapatite16,17,	inorganic	surfaces	binding	
peptides18	and	the	incorporation	of	silver	nanoparticles19.	Numerous	strategies	for	
incorporating	antimicrobial	agents	with	orthopaedic	implants	have	been	investigated,	
including:	i)	coating	titanium	with	polymers	loaded	with	antibiotics	for	sustained	release20,21,	
ii)	deposition	of	antimicrobial	ion	coatings	such	as	Ag	or	Cu22,23	and,	iii)	altering	the	
topography	of	the	surface24.	
These	approaches	have	also	been	exploited	for	incorporating	antimicrobials	into	HA	(and	
other	calcium	phosphate-based)	coatings.	Silver	ions	have	been	shown	to	display	high	
antimicrobial	efficiency	and	are	easily	incorporated	into	materials	such	as	hydroxyapatite	
through	an	ion	exchange	process25,26,27,28.	Antimicrobial	agents	have	been	added	on	to	the	
implant	surface	using	dip/spray	coating,	which	rely	on	adsorption	of	the	agent	on	to	the	
implant	surface.	However,	adsorbed	molecules	are	often	weakly	bound	to	the	implant	
surface	and	can	be	rapidly	desorbed	once	under	physiological	conditions.	The	leaching	of	
the	antimicrobial	from	the	surface	into	the	surrounding	area	following	implantation	may	
provide	relatively	short	term	potency	in	the	local	tissue	area19.	However,	rapid	desorption	of	
the	antimicrobial	correspondingly	reduces	the	antimicrobial	potency	at	the	implant	surface.	
Studies	on	titanium	have	shown	that	it	is	possible	to	utilise	the	strong	association	between	
the	titanium	oxide	passivation	layer	and	catechol	chemistry	to	give	a	stable	binding	of	an	
antibiotic	to	the	surface29.	However,	this	chemistry	is	not	directly	translatable	to	
hydroxyapatite.	Also	the	inclusion	of	antibiotics	such	as	cefotaxime	is	not	desirable	in	a	
clinical	setting	as	cefotaxime-resistant	species	are	already	established30.	If	an	infection	
occurs	from	these	bacteria	the	coating	would	then	be	ineffectual.		
Antimicrobial	peptides	(AMPs)	have	been	identified	as	promising	active	agents	against	
bacterial	and	fungal	microorganisms	due	to	their	broad	spectrum	of	activity	coupled	with	
low	toxicity.	However,	clinical	applications	and	commercial	development	of	these	
compounds	is	still	very	limited31.	Difficulties	in	their	production,	poor	optimisation	of	their	
properties	and	efficacy,	together	with	high	manufacturing	costs	have	contributed	to	the	
slow	transfer	from	research	to	clinical	practice	and	development	of	commercial	products32.	
The	rise	of	antibiotic–resistant	bacteria	is	stimulating	significant	interest	in	applying	AMPs	to	
biomedical	devices	and	translating	them	to	clinical	use.	The	main	sectors	of	application	of	
AMPs	are	mainly	those	of	prevention	and	control	of	infections	in	humans	and	animals,	while	
other	opportunities	can	also	be	foreseen	such	as	food	preservation	systems	and	utilization	
in	agricultural	and	environmental	protection.	
Antimicrobial	coatings	have	many	uses	in	medicine	and	include	coatings	for	implants33,	
catheters34,	and	dressings	for	wounds35,	There	are	several	AMP	compounds	that	are	
undergoing	clinical	trials	to	consider	combined	antimicrobial	and	immune-modulatory	
functions.	However,	at	present	no	drugs	based	on	AMPs	have	been	approved36.	Due	to	their	
chemical	nature	(peptides),	oral	and	intravenous	administration	of	AMPs	poses	problems	
due	to	possible	reduction	or	neutralization	of	the	active	ingredient	or	induction	of	an	
allergic	reaction37.	On	the	other	hand,	AMP	derived	drugs	appear	very	promising	
compounds	for	topical	formulations,	for	example	for	the	treatment	of	skin	burns/lesions,	
open	wounds,	and	the	protection	of	implanted	devices	ranging	from	catheters	to	contact	
lenses,	stents	and	artificial	tissue	substitute	applications.	Natural	methods	of	combating	
infection	in	the	body	include	defence	proteins	such	as	Defensins.	Defensins	are	small	
proteins	purified	from	granulocytes	that	display	high	levels	of	antimicrobial	activity38.	
Defensins	counteract	bacterial	invasion	of	the	body	through	direct	and	indirect	pathways.	
The	direct	pathway	involves	attacking	the	invading	pathogen	by	inducing	pore	formation	in	
the	membrane	of	the	cell,	leading	to	cell	lysis39.		Novel	synthetic	peptides	based	on	plant	
defensins	have	been	designed	and	shown	to	exhibit	good	levels	of	antimicrobial	activity40.	
Scudiero	et	al	used	human	β	defensins	as	a	model	for	novel	synthetic	peptides	and	
demonstrated	good	antimicrobial	activity.	However,	this	activity	was	reliant	on	the	localised	
ion	concentration	although	the	synthetic	analogues	were	not	as	susceptible	to	this	effect	as	
the	natural	defensin41.	
In	this	work	we	demonstrate	an	alternative	method	for	imparting	antimicrobial	activity	
upon	orthopaedic	implants.	The	method	employs	two	mechanisms	in	tandem	for	binding	a	
defensin	based	antimicrobial	peptide	(AMP)	to	a	hydroxyapatite	surface	with	the	aim	of	
providing	both	a	robust	long-term	antimicrobial	coating	of	the	implant	and	facilitating	
partial	release	of	the	antimicrobial	payload	into	the	surrounding	tissue.	This	uses	two	
different	methodologies,	a	covalent	attachment	of	the	peptide	(cAMP)	which	gives	a	
‘permanent’	coating	and	an	electrostatic	attachment	of	the	peptide	(eAMP)	which	is	
released	from	this	short	term	surface	coating	into	the	area	surrounding	the	implant	
sterilising	the	tissue	around	the	implant.	Employing	both	coatings	simultaneously	on	the	
same	surface	gives	a	dual	coating	(dAMP)	which	has	allowed	us	to	create	a	multi-functional	
antimicrobial	surface,	which	can	sterilise	the	surgical	site	and	prevent	colonisation	of	the	
implant	for	an	extended	period	of	time.	
	
		
Materials	and	methods	
Materials	
All	reagents	were	purchased	from	Sigma	(Poole,	UK),	unless	otherwise	stated.	Peptides	were	
purchased	from	Genscript	(Piscataway,	USA).	Bacteria	were	obtained	as	patient	isolates	
from	the	Queen	Elizabeth	Hospital,	Birmingham,	UK.	
	
Hydroxyapatite	synthesis	
HA	(for	both	electrostatic	and	covalent	studies)	was	prepared	using	the	following	steps.	
Aqueous	solutions	of	calcium	nitrate	1	M	(Fisher	Scientific	UK	Ltd.,	Loughborough,	UK)	and	
diammonium	hydrogen	phosphate	dibasic	0.6	M	were	prepared	and	the	pH	adjusted	to	10	
through	drop	wise	addition	of	37-39%	ammonium	hydroxide.	The	phosphate	salt	solution	
was	added	drop	wise	to	the	calcium	salt	solution	using	a	burette	while	stirring	and	
maintaining	a	pH	of	10	through	further	addition	of	ammonium	hydroxide.	After	ageing	
overnight	under	stirring,	the	nanocrystals	were	washed	by	five	cycles	of	centrifugation	at	
4000	rpm	and	resuspension	with	deionised	water	before	filtering.	Typical	yield	of	solid	
product	was	approximately	30	g,	with	1	g	resuspended	at	1	mg	per	mL	in	deionised	water	
adjusted	to	pH	7	and	dried	overnight	in	an	oven	at	60	°C	to	give	hydroxyapatite	as	a	powder.	
HA	pellets	for	electrostatic	studies	were	prepared	using	dried	hydroxyapatite	powder	mixed	
with	deionised	water	(830	μL	for	each	gram	of	HA)	to	form	a	thick	paste.	The	paste	was	put	
in	a	homemade	PTFE	mould	and	incubated	at	60	°C	overnight	before	sintering	at	1100	°C	for	
6	hours	with	a	temperature	ramp	rate	of	5	°C/min.	
Thiol	functionalised	hydroxyapatite	(tHA)	was	prepared	for	covalent	hydroxyapatite	studies.	
The	thiol	functionalisation	solution	consisted	of	3	%	(v/v)	(3-mercaptopropyl)	
trimethoxysilane	(MPTS)	stock	solution,	3	%	(v/v)	ultra-pure	deionised	water	and	94	%	(v/v)	
methanol.	The	water-methanol	mixture	was	prepared	before	adding	the	MPTS.	The	pH	was	
adjusted	slowly	to	4	by	addition	of	1	M	hydrochloric	acid	and	left	to	hydrolyse	for	4	hours.	
The	hydrolysed	MPTS	solution	was	then	pH	adjusted	to	7	by	addition	of	ammonium	
hydroxide	before	adding	the	cut	HA	pellets	and	leaving	it	to	react	overnight	while	on	a	flat	
shaker	plate	running	at	300	rpm	(ThermoScientific	Inc.,	Waltham,	MA,	USA).	
No	more	than	30	pellets	were	placed	in	each	reaction	bottle	at	a	time	in	order	to	ensure	
adequate	separation	and	coating	of	the	pellets.	The	pellets	were	carefully	washed	five	times	
in	20	%	methanol	before	drying	in	an	oven	for	2	hours	at	60	°C.	
	
eAMP	coating	of	HA	
The	moulded	HA	pellets	which	had	been	prepared	as	described	above	were	incubated	in	
eAMP	(5(6)-Carboxyfluorescein)	–	RRRRRRGALAGRRRRRRGALAGEEEEEEE,	(0.9	mM)	in	
phosphate	buffered	saline	(PBS)	for	30	minutes.	The	coated	pellets	were	then	removed	from	
the	solution	and	washed	five	times	with	PBS	and	stored	at	room	temperature	before	being	
used	for	studies.	
	
cAMP	coating	of	hydroxyapatite	
tHA	pellets	which	had	been	prepared	as	described	above	were	incubated	in	N,N-
dimethylformamide	(DMF)	(10	mL),	succinimidyltrans-4-(maleimidylmethyl)cyclohexane-1-
caboxylate	(SMCC)	(0.2	M)	and	the	cAMP	(5(6)carboxyfluorescein)	
RRRRRRGALAGRRRRRRGALAG	(0.9	mM)	for	12	hours	with	shaking.	The	covalently	coated	
pellets	were	removed	from	the	solution	and	washed	five	times	with	DMF	and	five	times	
with	PBS	before	being	used	in	studies.	
	
dAMP	coating	of	thiol-hydroxyapatite	
tHA	pellets	which	had	been	prepared	as	described	above	were	incubated	in	DMF	(10	mL),	
SMCC	(0.2	M)	and	the	cAMP	5(6)carboxyfluorescein)	RRRRRRGALAGRRRRRRGALAG	(0.9	
mM)	for	12	hours	with	shaking.	The	covalently	coated	pellets	were	removed	from	the	
solution	and	washed	five	times	with	DMF	and	five	times	with	PBS.	The	pellets	were	then	
incubated	in	eAMP	(5(6)-Carboxyfluorescein)	–	RRRRRRGALAGRRRRRRGALAGEEEEEEE,	(0.9	
mM)	in	phosphate	buffered	saline	(PBS)	for	30	minutes.	The	coated	pellets	were	then	
removed	from	the	solution	and	washed	five	times	with	PBS	and	stored	at	room	temperature	
before	being	used	for	studies.	Control	pellets	were	uncoated	HA	which	had	been	washed	in	
DMF	(5	x1	mL)	and	PBS	(5	x	1	mL).	
	
AMP	coating	of	hydroxyapatite	
As	a	control	for	release	studies	HA	pellets	were	coated	with	RRRRRRGALAGRRRRR	
5(6)carboxyfluorescein)	RRRRRRGALAGRRRRRRGALAG.	The	peptide	was	added	to	PBS	(10	
mL).	HA	pellet	was	added	to	the	solution	and	incubated	for	12	hours	with	shaking.	The	
pellets	were	removed	from	solution	and	washed	five	times	with	PBS.	
	
Quantification	of	peptide	on	hydroxyapatite	
Pellets	were	coated	as	described	above.	The	amount	of	peptide	remaining	in	the	reaction	
vessel	and	the	washes	was	quantified	using	fluorescence	of	the	5(6)	carboxyfluorescein	tag.	
This	was	then	used	to	calculate	the	remaining	peptide	which	had	been	immobilised	on	the	
surface.	
	
Release	of	AMP	from	eAMP	and	cAMP	surfaces	
eAMP,	cAMP	and	AMP	coated	pellets	were	incubated	in	PBS	(1	mL)	at	37	°	C	and	the	
solution	was	changed	at	each	time	point.	The	solutions	were	stored	in	the	dark	at	4	°C	and	
the	fluorescence	of	the	5(6)	carboxyfluorescein	tag	was	monitored	at	excitation/emission	
495/525	nm	on	a	Wallac	1420	plate	reader	(Perkin	Elmer,	London,	UK).	Percentage	values	
were	calculated	from	the	known	concentration	immobilised	on	the	surface.		
	
Stability	of	dAMP	coatings	
HA	pellets	were	coated	as	described	above.	Twelve	pellets	were	split	into	4	treatment	
groups	of	3	samples:	1)	HA,	2)	eAMP-HA,	3)	tHA,	4)	cAMP-tHA.	The	surface	of	the	pellets	
were	imaged	immediately	following	the	coating	procedure	to	ensure	the	coating	was	
present.	The	pellets	were	then	incubated	for	12	months	at	room	temperature	(20-24	°C)	in	
simulated	body	fluid	prepared	from	literature	sources42.	
	
At	7,	14	day	1	month	and	12	month	time	points	the	pellets	were	removed	from	the	
simulated	body	fluid	solution,	dried	and	viewed	with	an	Axioplan-2	fluorescence	microscope	
and	images	of	their	surfaces	obtained	with	Axiovision	software	(both	Carl	Zeiss	Ltd,	
Hertfordshire,	UK)	to	detect	residual	fluorescent	dAMP.	Peptide	on	the	surface	was	
quantified	using	established	methods43.	Briefly,	each	of	the	pellets	was	imaged	on	9	
different	areas	of	the	surface	(total	27	images/treatment).	The	levels	of	the	peptide	on	the	
surface	were	quantified	using	Image	J	(National	Institutes	of	Health).	All	images	were	taken	
at	the	same	exposure,	the	%	of	fluorescent	pixels	above	a	standardized	background	
threshold	calculated	using	Image	J.	
	
Proteolytic	stability	
cAMP	coated	pellets	were	coated	as	described	and	the	levels	of	fluorescence	on	the	
surfaces	quantified.	The	pellets	were	incubated	in	trypsin-edta	(1	mL,	0.02	M)	or	human	
leukocyte	elastase	(1	mL,	0.6	µg/mL	Merck	Millipore,	Nottingham,	UK)	for	2	hours.	The	
pellets	were	removed	from	the	solution	and	the	surfaces	washed	three	times	in	PBS	(1	mL).	
The	pellets	were	air	dried	in	the	dark	and	imaged	and	quantified	as	previously	described.				
	
Scanning	Electron	Microscopy	(SEM)	and	Energy-Dispersive	X-ray	
Spectroscopy	(EDX)	of	surfaces	
Surfaces	were	prepared	as	previously	described	for	fluorescence	microscopy.	The	samples	
were	studied	on	a	Philips	XL30	FEG	scanning	electron	microscope.	Imaging	was	carried	out	
in	triplicate	and	images	shown	are	representative	of	each	surface.	After	
SEM	samples	were	submitted	for	EDX.	Samples	were	run	in	triplicate	and	spectra	sites	were	
chosen	at	random	across	each	surface.	Data	presented	is	the	averages	of	all	spectra.	
	
Antimicrobial	efficacy	testing	of	AMP	on	laboratory	strains	of	bacteria	
The	minimum	inhibitory	concentration	(MIC)	of	the	prepared	AMP	against	various	bacteria	
was	determined	by	the	broth	dilution	method	according	to	the	recommendations	of	the	
British	Society	of	Antimicrobial	Chemotherapy44.	Briefly,	serial	dilutions	of	peptide	solutions	
were	prepared	at	3.7	–	0.002	mM	concentrations	made	up	in	lysogeny	(LB)	broth	and	tested	
against	S.	aureus	and	S.	epidermidis,	the	lowest	concentration	required	to	inhibit	bacterial	
growth	was	used.		
	
	
Antimicrobial	resistance	studies	
Bacterial	resistance	studies	were	then	carried	out	by	incubating	each	bacteria	in	LB	broth	
supplemented	with	50	%	of	the	concentration	of	the	peptide	required	to	get	an	MIC	
concentration.	Incubation	was	carried	out	at	37	°C	for	12	hours	and	the	MIC	test	repeated	
on	the	pre-treated	bacteria	as	described	above.			
Further	resistance	studies	were	carried	out	by	incubating	each	bacteria	with	0.003	mM	AMP	
concentration	and	then	doubling	the	concentration	of	AMP	every	24	hours	until	half	the	
MIC	value	was	reached.	At	each	time	point,	bacteria	were	sampled	using	the	MIC	assay	and	
the	MIC	noted.	These	studies	allow	one	to	establish	how	easily	resistance	might	be	
developed	to	the	AMP	peptide.	
	
Antimicrobial	tests	of	AMP	surfaces	
Antimicrobial	coated	HA	surfaces	were	tested	by	incubating	cAMP-tHA/dAMP-tHA	and	
uncoated	pellets	were	inoculated	with	10	μl	of	~109	colony	forming	units	(cfu)/ml	of	
coagulase-negative	S.	epidermidis,	S.	aureus	and	P.	aeruginosa.	Pellets	were	incubated	for	
24	hours	at	37	°C.	The	optical	density	of	LB	Broth	around	the	pellet	was	measured	at	600	nm	
using	a	spectrophotometer	(Jenway,	Stone,	UK).	The	pellet	surface	was	then	swabbed	and	
plated	out	on	LB	Agar.	The	plates	were	incubated	at	37	°	C	for	24	hours	and	the	number	of	
visible	colonies	on	the	plate	counted.			
		
Effect	of	serum	incubation	on	antimicrobial	efficacy	
dAMP	pellets	were	prepared	as	previously	described.	The	pellets	were	incubated	in	fetal	calf	
serum	(1mL)	for	4	hours.	The	pellets	were	washed	with	PBS	and	then	the	antimicrobial	
efficacy	was	tested	against	S.	aureus	as	described	above.	
	
Long	Term	Antimicrobial	Studies	
HA	and	dAMP-tHA	coated	pellets	were	incubated	in	LB	Broth	(1	mL)	and	inoculated	with	10	
μl	of	~109	colony	forming	units	(cfu)/ml	of	coagulase-negative	S.	epidermidis.	At	7,	14	and	21	
days	the	broth	was	tested	for	optical	density	to	determine	bacterial	number	and	the	
surfaces	swabbed	and	plated	out	on	LB	Agar.	The	agar	plates	were	incubated	at	37	°C	
overnight	and	the	colonies	counted.	
		
Toxicity	studies	of	AMP	and	dAMP	with	mammalian	cells	
Toxicity	studies	were	carried	out	using	osteoblast	precursor	cells	(MC3T3).	Cells	were	
detached	from	a	confluent	flask	and	seeded	at	50,000	cells/well.	The	media	(DMEM,	fetal	
bovine	serum	(10	%	v/v),	penicillin/streptomycin	(1	%	v/v)	was	supplemented	with	37	µg	of	
peptide/well.	At	each	time	point	the	cells	were	detached	from	the	plate	using	trypsin	(200	
µl).	The	cells	were	counted	using	a	haemocytometer.				
dAMP-tHA	were	placed	in	12	well	plate	and	seeded	with	50,000	cells	and	covered	with	
media	(1	mL).	Samples	were	prepared	separately	for	resazurin	and	cell	counts.	Samples	for	
resazurin	had	media	removed	and	were	washed	with	PBS.	The	pellets	were	resuspended	in	
fresh	media	(1	mL)	with	resazurin	(20	µl,	15mg/mL)	and	incubated	for	2	hours	at	37	°C.	
Aliquots	(200	µl)	of	the	media	were	removed	and	added	to	a	96	well	plate.	The	absorbance	
was	read	at	570	nm	on	a	(Wallac	Victor	3	1420	multilabel	counter).	Samples	for	cell	number	
had	the	media	removed	and	the	pellet	incubated	in	trypsin	(200	µl)	for	5	minutes	at	37	°C.	
The	cell	suspension	was	added	to	a	haemocytometer	and	counted.		
	
Toxicity	studies	were	carried	out	using	SAOS-2	cells	(Osteosarcoma	cells,	ECACC,	used	at	
passages	10-14).	
Cells	were	detached	from	a	confluent	flask	and	seeded	at	5,000	cells/well.	The	media	
(DMEM,	fetal	bovine	serum	(10	%	v/v),	penicillin/streptomycin	(1	%	v/v)	was	supplemented	
with	37	µg	of	peptide/well.	At	each	time	point	the	cells	were	detached	from	the	plate	using	
trypsin	(200	µl).	The	cells	were	counted	using	a	haemocytometer.				
Electrostatic	and	covalently	coated	HA	pellets	were	prepared	as	previously	described.	SAOS	
2	cells	were	seeded	onto	dAMP	coated	and	uncoated	HA	pellets	at	a	density	of	5000	
cells/pellet	in	500	μl	of	McCoys	5a	media	supplemented	with	10%	FBS	and	1	%	
Penicillin/Streptomycin	and	the	media	changed	every	3-4	days.	At	each	sample	time	point	
the	HA	pellets	with	their	attached	SAOS-2	cells	were	removed	from	the	media	and	gently	
washed	with	PBS	(3	x	1	mL).	The	cells	growing	on	the	HA	pellets	were	then	tested	for	
metabolic	activity	using	alamar	Blue	following	established	protocols35.	Briefly,	alamar	blue	
dye	(10	μl)	was	added	to	the	media	surrounding	the	cell	coated	pellets	and	incubated	for	2	
hours	and	then	the	absorbance	of	the	media	was	read	at	570	nm	on	a	Glomax	multi	
detection	system	(Promega,	Southampton,	UK).	The	cell	bearing	HA	pellets	were	then	
washed	in	PBS	to	remove	any	dead	cells,	then	placed	in	sterile	water	and	frozen	at	–	80	°C.	
The	samples	were	subjected	to	a	three	cycle	freeze	thaw	process	to	lyse	the	cells	and	
release	their	DNA	into	solution,	and	the	DNA	content	of	each	sample	was	measured	using	
Hoechst	33342	dye	to	assess	SAOS-2	cell	survival45.	
	
Statistics	
All	statistical	analyses	were	carried	out	using	SPSS	17.0	(IBM	SPSS	Inc.,	Chicago,	IL)	and	data	
were	presented	as	mean	±	SEM.	The	Shapiro-Wilk	test	was	used	to	ensure	all	data	was	
normally	distributed	before	parametric	testing	using	a	one-way	ANOVA	with	Tukey	post-hoc	
test	or	a	Mann-Whitney	U-Test.	The	statistical	significance	threshold	was	p<0.05.	
	
Results	
Peptide	design	and	synthesis	
AMPs	were	designed	using	sequence	matching	from	human	α	and	β	defensins.	Amino	acid	
residue	properties	including	positive/negative	charges	and	hydrophilic/hydrophobic	
patterns	were	compared	across	the	different	defensins	and	condensed	into	a	small	peptide	
sequence	pattern	which	was	then	synthesised	using	solid	phase	peptide	synthesis	(Figure	
1).	All	peptides	were	additionally	tagged	with	5(6)	carboxyfluorescein	(5(6)-CF)	to	allow	
visualisation	of	the	peptide	on	attachment	surfaces	and	peptide	quantification.	The	
individual	peptide	sequences	generated,	provided	a	toolkit	of	activity	(antimicrobial	activity,	
surface	binding	activity	or	both	antimicrobial	and	surface	binding	activity)	which	allowed	a	
mix	and	match	approach	to	building	candidate	peptides	for	binding	to	specific	surfaces	(e.g.	
the	RRRRRRGALAGRRRRRRGALAGGGGEEEEEEE	peptide	sequence	gave	a	broad	spectrum	
high	activity	AMP	which	binds	to	HA	electrostatically).	
	
The	cAMP	coating	was	characterised	using	energy-dispersive	X-ray	spectroscopy	
(EDX)	(Table	1).	This	data	showed	that	there	is	a	significant	increase	in	the	presence	of	Si	
between	HA	(0	±	0)	and	tHA	(0.2	±	0.08),	(p=0.002).	This	was	mirrored	by	the	increase	in	
sulfur	with	HA	(0	±0),	tHA	(0.37	±	0.10),	(p=0.000).	The	increase	in	sulfur	can	be	attributed	to	
the	sulfhydryl	groups	of	MPTS,	demonstrating	thiol	modification	of	the	surface.	This	was	
further	supported	by	raman	spectroscopy	(Supplementary	Information)	which	showed	a	
peak	at	2572	cm-1,	which	corresponds	to	the	S-H	stretching	mode,	as	well	as	2890	and	2923	
cm-1	which	are	the	CH2	vibrations	of	the	propyl	chain	of	the	MPTS.	The	cAMP-tHA	was	
characterised	by	EDX.	The	spectra	showed	a	significant	increase	in	the	amount	of	carbon	
present	on	the	surface	between	tHA	(8.78	±	0.44)	and	the	cAMP-tHA	(25.95	±	4.76),	
(p<0.000)	(Table	1).	The	increase	in	carbon	is	consistent	with	the	incorporation	of	the	
peptide	onto	the	surface.	The	amount	of	peptide	incorporated	onto	the	surface	was	
determined	to	be	0.54	mol/cm2	(cAMP)	and	1.78	mol/cm2	(eAMP).	The	calculations	also	
showed	a	1:1.2	cAMP	to	eAMP	ratio	in	dAMP	coated	pellets.		
		
Raman	spectroscopy	was	also	used	to	examine	the	composition	of	the	hydroxyapatite	to	
determine	if	tricalcium		phosphate	(TCP)	was	present	(supplementary	Information).	The	
spectra	showed	hydroxyapatite	peaks	with	slight	peak	broadening	suggesting	a	small	
amount	of	TCP	was	present	in	the	pellets.	
	
	
Surfaces	with	either	eAMP	or	cAMP	coating	were	imaged	for	surface	coverage	using	
fluorescence	microscopy	(Figure	2a-f),	which	showed	that	AMP	was	successfully	bound	to	
the	surface	with	good	coverage	immediately	following	both	covalent	and	electrostatic	
attachment.	The	coated	HA	pellets	were	incubated	in	simulated	body	fluid	for	1	month	with	
regular	changes	of	fluid	before	fluorescent	reimaging	to	visualise	residual	AMP	(both	eAMP	
and	cAMP),	and	this	showed	that	at	this	time	point	all	of	the	electrostatically	bound	peptide	
was	removed	from	the	HA	surface	(Figure	2a-c).	However,	with	covalent	functionalisation	
there	was	still	coverage	of	the	cAMP	on	the	tHA	surface	following	the	incubation	period	
(Figure	2d-f).	
Incorporation	of	the	binding	sequences	into	the	AMP	structure	allowed	the	electrostatic	
binding	to	HA	surfaces	to	give	a	sustained	peptide	release	profile	over	24	hours.	The	release	
profile	showed	that	100	%	of	the	eAMP	was	released	over	96	hours	(Figure	2	i).	This	is	
significantly	higher	than	cAMP	samples	which	showed	no	release	in	the	same	time	period.	
While	the	AMP	coating	with	no	specific	attachment	method	to	the	HA	showed	100	%	
release	at	8	hours.	The	long	term	stability	of	the	coating	was	examined	after	incubation	in	
PBS	for	12	months	(Figure	2g).	This	showed	no	significant	differences	in	the	levels	of	
fluorescence	immediately	after	coating	(1.3x106	±	7.2x104)	compared	to	after	incubation	for	
12	months	(1.2x106		±	3.8x104).	The	surfaces	also	showed	to	be	resistant	to	proteolysis	from	
both	human	leukocyte	elastase	(1.3x106	±	2.3	x104)	and	trypsin	(1.3	x106	±	5.6x104)	(Figure	
2h).	All	the	samples	were	significantly	higher	than	uncoated	samples	(83	±	85).		
	
The	surfaces	were	also	characterised	by	SEM	(Figure	2a-c).	This	showed	that	there	were	no	
differences	in	HA	structure	between	HA,	tHA	and	dAMP-tHA.	The	images	show	crystalline	
structures	consistent	with	hydroxyapatite.	
	
	
Antimicrobial	efficiency	of	antimicrobial	peptide	sequences	in	solution	
AMP	sequence	(RRRRRRGALAGRRRRRRGALAG)	was	tested	in	solution	against	a	broad	
spectrum	of	bacterial	species	including	clinical	isolates	(Table	2).	The	peptide	was	effective	
against	all	the	species.	The	peptide	showed	effectiveness	at	slightly	lower	concentrations	for	
Gram	positive	bacteria	(S.	aureus,	both	methicillin	sensitive	and	resistant,	S.	epidermidis	and	
enterococcus	spp.)	with	MICs	ranging	between	0.08-0.52	mM	when	compared	to	Gram	
negative	bacteria	(P.	aeruginosa,	K.	pneumoniae,	E.	coli	and	E.	cloacae)	which	had	MICs	
between	0.67	–	0.95	mM).		
AMP	were	tested	against	bacteria	commonly	found	in	implant	infections	(S.	aureus	and	S.	
epidermidis)	to	try	to	ascertain	the	AMP	ability	to	generate	resistant	bacteria.	When	the	
bacteria	were	preconditioned	in	two	different	ways	to	the	peptide	to	generate	resistance,	
no	resistance	was	observed.	However,	the	pre-treatment	of	the	bacteria	with	peptide	did	
affect	the	MIC	value	for	the	peptide	in	each	strain.	Incubation	overnight	of	the	bacteria	in	
half	the	MIC	of	the	peptide	did	reduce	the	MIC	concentration	in	S.	epidermidis	(Table	3).	
Consecutive	incubation	of	the	bacteria	with	increasing	concentration	of	peptide	resulted	in	
the	MIC	decreasing	at	each	concentration	for	both	S.	aureus	and	S.	epidermidis	(Figure	3).				
	
Antimicrobial	efficacy	AMP	coating	against	clinical	isolates	
eAMP,	cAMP	and	dAMP	coated	and	uncoated	HA	were	tested	to	determine	the	efficacy	of	
the	surface	against	clinical	isolates	commonly	found	in	orthopaedic	infections.	The	surfaces	
were	trialled	against	S.	aureus,	S.	epidermidis	and	P.	aeruginosa	the	most	commonly	found	
bacteria	in	orthopaedic	infections	(Figure	4).	The	data	demonstrated	that	both	the	cAMP	
and	dAMP	could	inhibit	growth	of	bacteria	on	the	hydroxyapatite	surfaces	(Figure	4a)	while	
eAMP	coating	alone	could	not	significantly	reduce	bacterial	colonisation	of	the	surface.	
Swabs	of	both	cAMP	and	dAMP	surfaces	showed	no	colony	forming	units	against	any	of	the	
bacteria	tested	(Figure	4a).	However,	the	cAMP	coating	could	only	reduce	the	levels	of	
planktonic	bacteria	in	solution	around	the	surface.	While	the	eAMP	and	dAMP	coatings	
could	successfully	inhibit	planktonic	growth	of	the	bacteria	in	solution	and	bacterial	
colonisation	on	the	surface	(Figure	4b).			
Efficacy	of	the	coating	after	incubation	in	serum	
Following	incubation	in	serum	the	efficacy	of	the	dAMP	at	inhibiting	growth	of	bacteria	in	
solution	was	not	significantly	different	from	dAMP	coated	HA	which	had	not	been	exposed	
to	serum.	Both	surfaces	were	significantly	lower	than	uncoated	HA	(	p<0.001)	(Figure	5a).	
However,	following	incubation	in	serum	the	efficacy	of	inhibiting	bacteria	on	the	surface	
was	slightly	although	not	significantly	reduced	when	compared	to	dAMP	coated	HA	which	
had	not	been	exposed	to	serum	(Figure	5b).	Both	dAMP	coated	HA	and	dAMP	coated	HA	
which	had	been	incubated	in	serum	had	significantly	lower	bacterial	colonisation	than	
uncoated	HA	(p<0.001).	
	
Long	term	antimicrobial	efficacy	against	S.	epidermidis	
dAMP-tHA	pellets	incubated	with	S.	epidermidis	over	3	weeks.	The	optical	density	of	the	
solution	surrounding	the	pellets	was	measured	each	week	which	showed	that	HA	surfaces	
had	significantly	higher	bacteria	number	with	optical	densities	of	0.12	±	0.02	at	week	1,	
increasing	to	0.27	±	0.04	at	week	2	and	0.35	±	0.06	at	week	3.	Compared	to	dAMP-tHA	
surfaces	at	week	1	(0.02	±	0.01),	week	2	(0.05	±	0.02)	and	week	3	(0.09	±	0.02)	(Figure	6a).	
After	3	weeks	the	surfaces	were	removed	from	the	LB	Broth	and	swabs	of	the	surfaces	were	
plated	to	show	that	the	dAMP-tHA	surfaces	still	had	not	been	colonised	by	the	bacteria	in	
this	time	compared	to	HA	surfaces	which	showed	high	bacterial	levels	(5.8x104	±	
5.3x104)(Figure	6b).						
	
Toxicity	of	the	peptide	in	culture	with	mammalian	cells.	
The	toxicity	of	the	peptide	alone	was	tested	in	both	osteoblast	precursor	cells	and	
osteosarcoma	cells	(Figure	7a-b).	The	peptide	demonstrated	no	toxicity	in	either	cell	type	
over	a	7	day	period.	In	osteoblast	precursor	cells	the	cell	number	increases	steadily	over	1	
week	from	1.7x105	±	2.5x105	(control)	and	2.0x105	± 1.5x105	(peptide)	at	day	1	to	1.7x106	± 
1.7x105	(control)	and	1.7x106	± 1.2x105	(peptide)	as	the	cells	reach	confluency	at	day	7.	In	
osteosarcoma	cells	the	cell	number	increases	from	9,895	±	96	(control)	and	9,391	±	113	
(peptide)	at	day	1	to	day	3	29,880	±	598	(control)	and	23,149	±	620	(peptide).	The	cell	
number	plateaus	over	the	following	four	days	with	final	readings	of	23,119	±	495	(control)	
and	24,718	±	2,166	(peptide).	Both	growth	curves	match	the	control	samples	of	cells	grown	
without	peptide	present	in	the	cell	media	with	no	statistical	differences	between	the	cell	
number	with	or	without	peptide	(Figure	7).		
	
Toxicity	of	the	dAMP	coating	on	HA	to	mammalian	cells.	
Osteoblast	precursor	cells	were	cultured	on	dAMP-tHA	and	HA	for	14	days	(Figure	8	a-b).	In	
both	treated	and	untreated	HA	the	cell	number	increased	up	to	day	7,	1.6x106	±	1.8x105	
(peptide	coated)	and	1.6x106	±	2.2x105		and	then	plateaued.	Although	the	cell	number	
appears	to	decrease	at	day	14	there	was	no	significant	difference	between	day	9	peptide	
coated	(1.4x106	±	1.5x105),	control	(1.5x106	±	7.9x105)		and	day	14	peptide	coated	(1.1x106	±	
6.2x105),	control	(1.0x106	±	4.6x105).	The	cell	number	followed	the	same	growth	pattern	on	
both	dAMP-tHA	and	HA	with	no	significant	differences	between	the	two	groups.	Over	the	14	
days	the	osteosarcoma	cell	number	increased	up	to	day	3	peptide	coated	(2.2x104	±	395),	
control	(2.9x104	±	1713)			and	then	plateaued	with	no	significant	differences	between	the	
time	points	day	3-14,	peptide	coated	(2.3x104	±	158),	control	(2.6x104	±	1133)		(Figure	8).	
There	were	no	significant	differences	between	the	dAMP-tHA	and	HA	groups	indicating	that	
the	dAMP	did	not	demonstrate	toxicity	to	the	cells	when	bound	onto	a	surface.		
	
Discussion	
As	infection	is	established	as	a	major	complication	of	orthopaedic	surgery,	there	have	been	
multiple	attempts	to	manipulate	the	host-device	interface	by	the	addition	of	antimicrobial	
agents17,18.	While	there	has	been	a	good	deal	of	success,	the	main	barrier	to	clinical	
translation	has	been	the	lack	of	ability	to	tailor	implant	material	chemistry	at	a	molecular	
scale	and	a	reliance	on	incorporating	agents	with	a	secondary	material	phase	on	to	the	
implant	surface.	An	implant	formed	from	titanium	with	a	polymer	surface	coating,	which	is	
then	covalently	functionalised	changes	the	properties	of	the	implant	for	the	host	tissue	and	
correspondingly	the	host	tissue	response	to	the	device.	
By	binding	peptides	to	the	surfaces	of	material	such	as	hydroxyapatite	directly	we	aim	to	
leave	as	much	of	the	original	material	‘visible’	to	the	host	tissue	as	possible	and	therefore	
retain	the	osseointegrative	properties	of	the	implant	the	peptide	coating	has	a	surface	
density	of	1	molecule	/	nm.	This	suggesting	the	cells	will	still	be	able	to	attach	to	the	
hydroxyapatite.	While	previous	studies	have	demonstrated	that	the	idea	of	dual	coating	is	
possible	on	different	surfaces,	all	of	the	coatings	rely	on	the	deposition	of	polymers	which	
mask	the	surface	completely	changing	the	material	surface	properties	exposed	to	the	in	vivo	
environment	to	the	body46.	In	this	work	we	are	tailoring	the	surface	chemistry	of	the	
implant	and	tethering	the	antimicrobial	peptides	directly	onto	the	surface	in	order	to	inhibit	
bacterial	growth.	The	scanning	electron	microscopy	images	support	that	the	macroscale	of	
the	material	is	unchanged	and	the	cell	growth	experiments	have	shown	that	the	nanoscale	
changes	have	not	affected	the	cell	response	to	the	material.	
		
The	defensin	sequence	synthesised,	based	on	human	defensin	sequences,	showed	
comparable	levels	of	antimicrobial	efficacy	to	human	defensins47.	While	these	values	can	
vary	depending	on	the	environment,	this	comparison	crucially	demonstrates	that	the	
efficiency	of	the	antimicrobial	sequences	is	unchanged	by	the	shorter	peptide	length	and	
simplification	of	the	sequence.	One	real	potential	of	the	peptide	sequence	presented	here	is	
the	apparent	inability	of	the	bacteria	to	develop	resistance	in	the	studies	carried	out.	This	is	
believed	to	be	due	to	the	proposed	mechanism	of	action	of	the	peptide.	Antimicrobial	
peptides	are	known	to	insert	into	bacterial	cells	causing	pore	formation48.	This	destabilises	
the	membrane	and	triggers	cell	lysis	and	death49.	The	positively	charged	AMP	will	associate	
strongly	with	the	negative	charges	found	in	the	bacterial	cell	wall50.	This	allows	the	
hydrophobic	regions	of	the	peptide	to	induce	pore	formation.	The	bacteria	will	struggle	to	
develop	resistance	to	this	as	it	would	demand	either	removal	or	complete	restructuring	of	
the	bacterial	cell	wall.	With	antimicrobial	resistance	becoming	a	global	problem,	developing	
antimicrobial	surfaces	for	clinical	applications,	against	which	bacteria	struggle	to	present	
resistance	to	is	of	great	interest	to	the	clinical	community51.	While	further	studies	are	of	
course	required,	this	presents	a	promising	outlook	for	the	AMP.	Long	term	studies	into	
antimicrobial	coated	implants	have	demonstrated	that	after	5	years	the	implants	are	
colonised	and	the	bacteria	are	resistant	to	the	chosen	antibiotic52.	By	using	a	broad	
spectrum	antimicrobial	peptide	(that	the	bacteria	cannot	rapidly	develop	resistance	to)	
ensures	that	colonisation	of	the	surface	will	not	occur.	
	
Mikos	et	al	demonstrated	that	short	sequence	polyglutamic	acid	residues	can	bind	strongly	
to	the	surface	of	hydroxyapatite53.	Our	work	here	has	demonstrated	that	the	inclusion	of	
the	binder	sequence	does	not	hinder	the	efficacy	of	the	peptide	and	ensures	that	the	
solution	around	the	surface	can	be	sterilised	in	the	short	term.	In	the	long	term	studies	the	
efficacy	of	the	surface	at	sterilising	the	solution	surrounding	it	was	reduced	as	the	
electrostatically	bound	peptide	was	removed	over	sequential	broth	changes.	
	
The	stability	of	the	cAMP	to	long	term	incubation	supports	the	spectroscopic	data	that	the	
peptide	has	formed	a	covalent	bond	with	the	surface	which	will	not	allow	the	peptide	to	
desorb	from	the	surface.	The	apparent	stability	of	the	peptides	to	proteoloytic	degradation	
is	due	to	steric	hindrance.	As	the	peptides	are	grafted	directly	to	the	surface	without	linker	
spacer	units,	the	hydroxyapatite	surface	provides	a	large	amount	of	steric	hindrance	around	
the	peptides.	The	high	coverage	of	peptide	across	the	surface	also	provides	steric	bulk	
preventing	access	to	the	peptide	chain.	This	prevents	the	enzymes	such	as	proteases	
reaching	the	regions	on	the	chain	it	can	activate,	and	gives	the	AMP	coating	its	high	stability	
profile.		
	
The	stability	of	the	covalent	functionality	of	the	dAMP	coating	also	supports	translation	of	
this	work.	The	coating	is	shown	to	be	stable	up	to	12	months	in	simulated	body	fluid	with	
motion	and	change	of	the	solution	surrounding	the	surface.	This	suggests	that	the	coating	
will	retain	stability	in	the	body	and	give	a	long	lasting	coating	on	the	implant	preventing	
biofilm	formation	without	displaying	cytotoxicity.	The	long	term	microbiological	efficacy	
study	demonstrated	that	not	only	did	the	surface	maintain	its	efficacy	in	optimum	bacterial	
growth	conditions,	but	that	the	dAMP	surface	still	significantly	reduced	the	number	of	
planktonic	bacteria	in	solution	despite	the	eAMP	coating	dissociation	and	removal	in	the	
initial	broth	changes.	This	demonstrates	that	the	covalent	bond	form	of	the	peptide	is	
effective	at	maintaining	surface	sterilisation	and	may	reduce	bacteria	number	overall	in	a	
closed	system	by	eliminating	bacteria	when	they	come	into	contact	with	the	surface.	
	
Previous	work	on	the	surface	chemistry	of	hydroxyapatite	by	Williams	et	al	has	shown	that	
it	is	possible	to	alter	the	surface	chemistry	of	the	hydroxyapatite	to	include	thiol	residues	
without	significantly	altering	the	material	properties54.	This	has	allowed	us	to	use	the	thiol	
groups	to	act	as	tethering	sites	to	covalently	link	the	antimicrobial	peptides.	This	gives	
permanent	functionalisation	with	the	peptide	without	compromising	the	bulk	properties	of	
the	material	as	evidenced	by	the	SEM	images.	From	a	biological	perspective	cell	
proliferation	and	metabolic	activity	studies	showed	the	AMP	coating	had	no	cytotoxic	
effects.	
	
The	results	we	present	here	have	shown	that	the	thiol	modification	has	occurred	(both	EDX	
and	Raman	data,	Table	1	and	Figure	s1).	The	EDX	also	demonstrates	that	we	can	develop	
this	technique	further	and	attach	the	antimicrobial	peptides	to	the	free	thiol	functionality.	
The	fluorescence	spectroscopy	images	demonstrates	that	this	technique	can	be	used	to	coat	
bulk	material	over	large	surface	areas.	This	makes	the	case	for	translation	of	the	dAMP	
coating	into	clinical	application	very	strong.	
	
The	development	of	these	dual	surface	coatings	which	impart	both	short	term	and	long	
term	antimicrobial	functionality	are	vitally	important	for	orthopaedic	infection	as	infection	
can	occur	at	the	time	of	surgery	or	at	later	time.	This	results	in	a	need	for	a	dual	coating	
which	can	sterilise	the	area	surrounding	the	implant	at	the	time	of	surgery	and	give	long	
lasting	functionality55,56.	The	data	presented	here	demonstrates	that	although	both	cAMP	
and	eAMP	are	efficacious,	neither	alone	can	inhibit	both	the	planktonic	and	surface	growth	
of	bacteria.	The	dAMP	coating	can	inhibit	both.	
	
In	summary,	in	the	fight	to	treat	infection	following	implantation	of	a	prosthesis,	there	are	
several	important	needs	which	must	be	met	within	the	host-device	interface:	1)	Short	term	
delivery	of	antimicrobial	agents	to	sterilise	the	host	tissue	and	device	to	prevent	
colonisation	by	bacteria.	2)	Long	term	stable	antimicrobial	coatings	to	prevent	bacterial	
colonisation	of	the	implant	surface.	3)	No	alteration	of	the	material	properties	of	the	
implant	device	which	would	compromises	the	ability	of	the	implant	to	integrate	with	native	
bone	tissue.	To	the	best	of	our	knowledge,	these	needs	are	unmet	at	the	current	state	of	
the	art	in	the	field.	There	are	many	studies	showing	coating	of	orthopaedic	devices	by	
dip/spray	coating	or	incorporation	of	antimicrobial	agents	during	production	and	these	give	
excellent	materials57,58.	However,	these	materials	only	provide	short	term	antimicrobial	
activity	(<12	months),	failing	to	tackle	the	whole	problem.	There	has	been	further	work	on	
coating	devices	with	polymers,	which	can	then	have	antimicrobial	agents	‘permanently’	
attached	but	this	method	changes	the	properties	of	the	implant	material	due	to	the	
inclusion	of	the	polymer	material.	We	have	addressed	this	problem	by	incorporating	the	
dual	antimicrobial	surface	coating	which	facilitates	short	term	release	as	well	as	a	long	term	
stable	antimicrobial	presence	at	the	material	surface.	
	
Conclusions	
We	have	demonstrated	the	manufacture	of	a	novel	dual	system	approach	to	prevent	
antimicrobial	infections	which	utilises	two	different	binding	mechanisms	for	the	same	
antimicrobial	sequence.	The	electrostatically	released	peptide	inhibits	bacterial	growth	in	
solution	while	the	covalently	bonded	peptide	inhibits	adherence	and	biofilm	formation.	
Both	together	can	inhibit	the	colonisation	of	bacteria	at	the	interface	of	an	engineered	
surface	with	tissue,	while	maintaining	cell	growth.	The	peptides	can	be	tailored	to	interact	
with	a	surface	and	maintain	good	efficacy	against	a	broad	spectrum	of	bacteria	and	show	
strong	antimicrobial	activity	against	clinical	isolates	of	S.	aureus,	S.	epidermidis	and	P.	
aeruginosa	(the	bacteria	most	commonly	found	in	joint	infections).	By	using	our	mix	and	
match	system	combining	multiple	fragments	with	different	properties	(surface	binding	and	
antimicrobial	activity)	without	compromising	the	individual	functions,	the	dAMP	coating	
gives	short	term	sterilisation	of	the	neighbouring	tissue,	followed	by	long-term	sustained	
antimicrobial	activity	of	the	surface.	With	this	work	established,	further	work	is	needed	to	
test	the	peptide	coatings	in	a	preclinical	animal	infection	model	to	move	them	towards	a	
clinical	environment.	
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Figure	1.	(a)	The	sequence	of	human	defensins	a1,	2	and	3	with	the	nature	of	the	amino	
acids	highlighted.	The	main	patterns	are	then	shown	pictorially.	The	sequences	of	the	first-	
and	second-generation	peptides	are	shown	with	the	nature	of	the	amino	acids	indicated	by	
colour.	(b)	The	attachment	of	the	peptide	to	the	HA	through	both	electrostatic	binding	and	
covalent	linkages.	
	
	
Figure	 2.	 Fluorescence	 microscopy	 images	 of:	 (a)	 HA;	 (b)	 HA	 coated	 with	 electrostatic	
coating,	 imaged	 immediately	 after	 washing	 following	 coating;	 (c)	 HA	 coated	 with	
electrostatic	coating,	after	samples	had	been	stored	in	simulated	body	fluid	for	one	month	
with	 changes	 every	 7	 days;	 (d	 )	 thiol-modified	 HA;	 (e)	 thiol-modified	 HA	 with	 covalent	
coating,	 imaged	 immediately	 after	 washing;	 (f	 )	 thiol-modified	 HA	 with	 covalent	 coating,	
after	samples	had	been	stored	in	simulated	body	fluid	for	one	month	with	changes	every	7	
days	before.	All	 images	are	representative	of	all	 sample	surfaces.	 (g)	Quantification	of	 the	
fluorescence	on	 the	 covalently	 coated,	 thiol-modified	HA	over	 time,	 showing	 the	 average	
surface	 pixel	 count,	 n	 .	 3,	 and	 error	 bars	 show	 the	 standard	 error	 of	 the	 mean.	 (h)	
Quantification	 of	 the	 fluorescence	 on	 the	 covalently	 coated,	 thiol-modified	 HA	 after	
treatment	with	 proteases,	 n	 .	 3,	 and	 error	 bars	 show	 the	 standard	 error	 of	 the	mean.	 (i)	
Release	 from	the	eAMP,	cAMP	and	AMP	coatings	 from	the	surface	over	96	h,	n	 .	3,	error	
bars	show	the	standard	error	of	the	mean.	
	
Table	1:	Table	1.	Elemental	composition	(%	wt)	of	the	substrate	and	functionalized	substrate	
as	determined	through	EDX	measurements.	Values	shown	are	the	averages	±	standard	
deviation	of	5	readings	taken	at	different	points	across	the	surface	of	each	pellet.	
 Ca P C O Si S 
Hydroxyapatite 29.39	±	0.64 16.74	±	0.74 6.93	±	0.35 46.94	±	0.44 0	±	0 0	±	0 
Hydroxyapatite	–	
thiol	modified 
31.62	±	0.93 16.25	±	0.43 8.78	±	0.44 42.40	±	1.13 0.2	0	±	0.08 0.37	±	0.10 
Hydroxyapatite	
dAMP 
19.50	±	2.72 11.94	±	1.28 25.95	±	4.76 41.99	±	1.76 0.24	±	0.04 0.39	±	0.04 
	
Table	2:	Minimum	Inhibitory	Concentration	(MIC)	of	AMP	against	clinically	isolated	bacteria.	
Bacteria MIC	(mM)	±	SEM 
P.	aeruginosa 0.87	±	0.19 
K.	pneumoniae 0.95	±	0.13 
E.	Coli 0.67	±	0.18 
Enterobacter	cloacae 0.74	±	0.18 
S.	aureus	(methicillin	sensitive) 0.37	±	0.03 
S.	aureus	(methicillin	resistant) 0.35	±	0.07 
S.	epidermis	(Coagulase	negative) 0.08	±	0.03 
Enterococcus	spp. 0.52	±	0.31 
	
Table	3:	The	effect	of	peptide	pre-incubation	with	bacteria	on	Minimum	Inhibitory	
Concentration	
Bacteria MIC	(naïve	bacteria) MIC	(preconditioned	24	
hours	) 
S.	aureus	(NCTC	8532) 
0.9	mM 0.9	mM 
S.	Epidermis	(C8	-	clinical	
isolate) 0.9	mM 0.2	mM 
	
	
	
Figure	3.	MIC	for	S.	aureus	and	S.	epidermidis	after	incubation	in	increasing	concentrations	
of	AMP,	shown	as	a	percentage	of	the	initial	MIC	required	to	inhibit	growth	in	naive	
bacteria.	
	
	
	
	
	
	
	
	
		
Figure	4.	 (a)	The	number	of	 colony-forming	units	 found	on	cAMP–tHA,	dAMP–tHA	or	 tHA	
after	incubation	with	S.	aureus,	S.	epidermidis	and	P.	aeruginosa.	Error	bars	show	standard	
error	 of	 the	 mean,	 n	 =	 6,	 ***p<0.000.	 (b)	 The	 absorbance	 of	 the	 bacteria	 in	 broth	
surrounding	 the	 surface	 at	 600	 nm	 for	 S.	 epidermidis,	 S.	 aureus	 and	 P.	 aeruginosa	 in	 the	
solution	 surrounding	a	 cAMP-tHA/eAMP-tHA/dAMP-tHA	or	 tHA.	Error	bars	 show	standard	
error	of	the	mean,	n	=	6,	**p	<	0.001,	*p	<	0.05.	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	5.	 (a)	The	number	of	colony-forming	units	of	S.	aureus	found	on	dAMP–tHA	or	tHA	
with	and	without	a	4	h	incubation	in	serum.	Error	bars	show	standard	error	of	the	mean,	n	=	
6,	***p	<	0.000.	(b)	The	absorbance	of	the	bacteria	in	broth	surrounding	the	surface	at	600	
nm	 of	 dAMP–tHA	 or	 tHA	 with	 and	 without	 a	 4	 h	 incubation	 in	 serum.	 Error	 bars	 show	
standard	error	of	the	mean,	n	=	6,	***p	<	0.001,	*p	<	0.05.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
Figure	6.	(a)	The	survival	of	S.	epidermidis	in	the	solution	surrounding	the	dAMP–tHA	pellet	
at	1,	2	and	3	weeks	compared	with	HA	measured	using	optical	density.	(b)	Survival	of	S.	
epidermidis	on	the	surface	of	the	dAMP–	tHA	pellet	compared	with	the	HA	pellet	after	three	
weeks	in	culture.	Error	bars	show	standard	error	of	the	mean,	n	=	6.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure 7. (a) Osteoblast precursor cells grown on tissue culture plastic with and 
without AMP in the cell media throughout growth. (b) Osteosarcoma cells grown on 
tissue culture plastic with and without AMP in the cell media, n = 6, error bars show 
standard error of the mean. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
Figure	8.	(a)	Osteoblast	precursor	cells	grown	on	dAMP–tHA	pellets	compared	with	
osteoblast	precursor	cells	grown	on	HA	pellets.	(b)	Osteosarcoma	cells	grown	on	dAMP–tHA	
pellets	compared	with	HA	pellets.	Error	bars	show	standard	error	of	the	mean,	n	=	6.	
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